186 related articles for article (PubMed ID: 28677687)
1. TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Pirovano G; Ashton TM; Herbert KJ; Bryant RJ; Verrill CL; Cerundolo L; Buffa FM; Prevo R; Harrap I; Ryan AJ; Macaulay V; McKenna WG; Higgins GS
Br J Cancer; 2017 Aug; 117(4):503-512. PubMed ID: 28677687
[TBL] [Abstract][Full Text] [Related]
2. Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Herbert KJ; Puliyadi R; Prevo R; Rodriguez-Berriguete G; Ryan A; Ramadan K; Higgins GS
Cell Death Differ; 2021 Apr; 28(4):1333-1346. PubMed ID: 33168956
[TBL] [Abstract][Full Text] [Related]
3. Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer.
Zhao R; Huang H; Choi BY; Liu X; Zhang M; Zhou S; Song M; Yin F; Chen H; Shim JH; Bode AM; Dong Z; Lee MH
Phytomedicine; 2019 Aug; 61():152813. PubMed ID: 31035049
[TBL] [Abstract][Full Text] [Related]
4. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract][Full Text] [Related]
5. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
6. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
7. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
8. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
9. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
10. [
Pirovano G; Roberts S; Brand C; Donabedian PL; Mason C; de Souza PD; Higgins GS; Reiner T
Mol Imaging Biol; 2019 Aug; 21(4):705-712. PubMed ID: 30357568
[TBL] [Abstract][Full Text] [Related]
11. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
13. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
14. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.
Park JH; Yoon DS; Choi HJ; Hahm DH; Oh SM
J Biol Chem; 2013 Feb; 288(5):3585-93. PubMed ID: 23250755
[TBL] [Abstract][Full Text] [Related]
16. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
17. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
18. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
19. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
20. Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins.
Rizkallah R; Batsomboon P; Dudley GB; Hurt MM
Oncotarget; 2015 Jan; 6(3):1446-61. PubMed ID: 25575812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]